Science Signaling · 2015 · 49 citations · 44 references
Life SciencesCell BiologyImmunologyCell SignalingImmunoregulationSignal TransductionB Cell BiologyB Cell RegulationCytokine BiologyCytokine Receptor SignalingHumoral ImmunityImmune Cell SignalingAdaptor Protein SignalingB Cell Survival SignalingB-cell PathogenesisCytokine Signaling In B Cell DevelopmentLoss-of-function MutationsPlasma Cell BiologyPlasma Cell DifferentiationStat3 Signaling
Tumor necrosis factor receptor-associated factor 3 (TRAF3) is an adaptor protein that inhibits signaling by CD40 and by the receptor for B cell-activating factor (BAFF) and negatively regulates homeostatic B cell survival. Loss-of-function mutations in TRAF3 are associated with human B cell malignancies, in particular multiple myeloma. The cytokine interleukin-6 (IL-6) supports the differentiation and survival of normal and neoplastic plasma cells. We found that mice with a deficiency in TRAF3 specifically in B cells (B-Traf3(-/-) mice) had about twice as many plasma cells as did their littermate controls. TRAF3-deficient B cells had enhanced responsiveness to IL-6, and genetic loss of IL-6 in B-Traf3(-/-) mice restored their plasma cell numbers to normal. TRAF3 inhibited IL-6 receptor (IL-6R)-mediated signaling by facilitating the association of PTPN22 (a nonreceptor protein tyrosine phosphatase) with the kinase Janus-activated kinase 1 (Jak1), which in turn blocked phosphorylation of the transcription factor STAT3 (signal transducer and activator of transcription 3). Consistent with these results, the number of plasma cells in the PTPN22-deficient mice was increased compared to that in the wild-type mice. Our findings identify TRAF3 and PTPN22 as inhibitors of IL-6R signaling in B cells and reveal a previously uncharacterized role for TRAF3 in the regulation of plasma cell differentiation.
44
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Manfred Köpf, Heinz Baumann, Giulia Freer et al. · Nature · 1994 · 1.8K citations
Life Sciences, Immunology, Pathology +16
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Michio Kawano, Toshio Hirano, Tadashi Matsuda et al. · Nature · 1988 · 1.7K citations
Medicine, Immunology, Oncology +11
Interleukin-6 family of cytokines and gp130
Tadamitsu Kishimoto, Shizuo Akira, Masashi Narazaki et al. · Blood · 1995 · 1.3K citations · Full text
Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma
Jonathan J. Keats, Rafaël Fonseca, Marta Chesi et al. · Cancer Cell · 2007 · 988 citations · Full text